

MEDICATION STANDING ORDER

HIGH-ALERT MEDICATION ¹

Version date: 2023-12-14

Effective date: 2024-01-16 (0700)

INDICATIONS

• Cardiac arrest due to ventricular fibrillation (VF), pulseless ventricular tachycardia (pVT), asystole, or pulseless electrical activity (PEA) ³

CONTRAINDICATIONS

• None

ROUTE (WORK SCOPE)	INITIAL DOSE	REPEAT DOSE	
INTRAVENOUS / INTRAOSSEOUS (ICP & ABOVE)	10 years & older - 1 mg	Every 3 to 5 minutes as required	
	72 hours up to 10 years - 0.01 mg/kg (max 1 mg)		

WEIGHT (kg)	DOSE (mg)	VOLUME (ml)	WEIGHT (kg)	DOSE (mg)	VOLUME (ml)
5 to 10	0.1	1	56 to 60	0.6	6
11 to 15	0.15	1.5	61 to 65	0.65	6.5
16 to 20	0.2	2	66 to 70	0.7	7
21 to 25	0.25	2.5	71 to 75	0.75	7.5
26 to 30	0.3	3	76 to 80	0.8	8
31 to 35	0.35	3.5	81 to 85	0.85	8.5
36 to 40	0.4	4	86 to 90	0.9	9
41 to 45	0.45	4.5	91 to 95	0.95	9.5
46 to 50	0.5	5	96 to 100	1	10
51 to 55	0.55	5.5	> 100	1	10

1. ERS HIGH-ALERT MEDICATION: Refer to Shared Health Provincial Clinical Standard - Safety Controls for High-Alert Medications (refer to A03 - HIGH ALERT MEDICATIONS).

NOTES

- 2. Administer by rapid push, follow each dose with a saline flush in adults and adolescents, and elevate the arm for 10 to 20 seconds if possible.
- 3. Do not mix with sodium bicarbonate.
- 4. Administer as early as possible in cardiac arrest with a non-shockable rhythm (asystole or PEA).

APPROVED BY				
Bufterel	Jefeman L.			
Medical Director - Provincial EMS/PT	Associate Medical Director - Provincial EMS/PT			

VERSION CHANGES (refer to X08 for change tracking)

• Addition of Shared Health Provincial Clinical Standard for high-alert medications